IBIO:NASDAQiBio, Inc. analysis
Data as of Sep 30, 2026 - not real-time
- Latest price
- $1.17
- Risk: high
- 9/10High risk
Summary
iBio, Inc. is priced at $1.17 and its moving averages line up in bearish order, the shorter trailing the longer. Across the trailing 30 sessions it lost 19.3%. Momentum indicators put RSI at 36.8 (approaching oversold) with MACD reading bearish. Recent trading has carved out support near $1.15 and resistance around $1.37.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 386.2% above where the shares trade now. Revenue is contracting at 100.0%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 46.5%, a beta of 2.12 and a maximum drawdown of 61.9%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Near-term and long-term part ways here — sell short-term against hold longer out, with 1/10 conviction on the long call.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 386.2% above where the shares trade now. Revenue is contracting at 100.0%.
Risk comes out at 9 of a possible 10, a high reading. With 30-day volatility of 46.5%, a beta of 2.12 and a maximum drawdown of 61.9%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Near-term and long-term part ways here — sell short-term against hold longer out, with 1/10 conviction on the long call.
Top market events
- Ibio Reports Fiscal Year 2026 Financial Results And Provides Corporate Update.
Market outlook
Short term
< 1 yearCautious
Model confidence4/104 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 1.83
- MACD momentum is negative
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- Trading below the 200-day average of 1.83
- Analyst targets imply +386.2% versus the current price
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +386.2% versus the current price
- Negative return on equity of -65.7%
- Revenue contracting at -100.0%
Key metrics
Financial health
Revenue Growth-100.00%
P/E Ratio-1.9
ROE-65.70%
ROA-30.80%
Debt/Equity2.56
P/B Ratio0.8
Op. Cash Flow$-23218000
Free Cash Flow$-13621375
Industry P/E30.5
Technical analysis
TrendBearish
RSI36.8
Support$1.15
Resistance$1.37
MA 20$1.24
MA 50$1.35
MA 200$1.83
MACDBearish
VolumeIncreasing
Fear & Greed Index92.79
Valuation
Target Price$5.69
Upside/Downside386.23%
GradeUndervalued
TypeBlend
Risk assessment
Beta2.12
Volatility46.47%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.